Avastin-Tarceva combo falls short in trial

A high-powered drug combo didn't make the grade in a new lung cancer trial. Combining Genentech's Avastin and OSI Pharmaceuticals' Tarceva didn't boost survival for patients who had not responded to chemotherapy, failing the trial's primary endpoint. Release | Report

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.